BNP as a Predictor of Cardiovascular Disease and All Cause Mortality. Dr. Thierry Le Jemtel

Similar documents
Natriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Biomarkers in the Assessment of Congestive Heart Failure

An Update & Suggestions on How to Use It

Lnformation Coverage Guidance

ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

Measuring Natriuretic Peptides in Acute Coronary Syndromes

The clinical value of natriuretic peptide testing in heart failure

ESCBM meeting 2018, Prague Utility of Cardiac Biomarkers in Clinical Heart Failure Care. Md. Shahidul Islam, M.D., Ph.D

B-type Natriuretic Peptide in VHD: a Non-imaging Helper for the Cardiologist. Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM

Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association

Improving Diagnostic, Prognostic & Therapeutic Biomarkers in Heart Disease. Professor Mark Richards Medicine, University of Otago, Christchurch

Post Hoc Analysis of the PARADIGM Heart Failure Trial:

A Guide to Proper Utilization of Biomarkers

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.

Plasma MR-proADM is superior to NTproBNP for all-cause short term mortality prediction in acute pulmonary embolism.

Clinical Investigations

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1

Learning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III

Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?


Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Supplement materials:

Australian Journal of Basic and Applied Sciences, 9(36) December 2015, Pages: ISSN: Journal home page:

Ruolo dei Marcatori Bioumorali nello scompenso cardiaco

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Severe aortic stenosis should be operated before symptom onset CONTRA. Helmut Baumgartner

Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery

6/6/17. Heart Failure and Natriuretic Peptides. Learning objectives

Heart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.

Recent literature highlights the high negative

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Is B-type natriuretic peptide a risk factor for heart failure in patients treated with bardoxolone methyl?

Heart Failure. A Marvellous Story with More to Come. Prof Ken McDonald National Clinical Lead for Heart Failure

Supplementary Online Content

DECLARATION OF CONFLICT OF INTEREST

Original Article Brain Natriuretic Peptide as the long-term cause of mortality in patients with cardiovascular disease: a retrospective cohort study

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

TROPONINS HAVE THEY CHANGED YOUR

University of Groningen. BNP and NT-proBNP in heart failure Hogenhuis, Jochem

Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;

Natriuretic peptides and cardiovascular diseases: from old concepts to novel perspectives

Diagnosis is it really Heart Failure?

Diagnostic value of N-terminal ProB-Type Natriuretic Peptide in Emergency Department: Analysis by subgroups

10 years evaluation of soluble ST2 level and incidence of diastolic

Mario Plebani University-Hospital of Padova, Italy

ΟΙ ΒΙΟΔΕΙΚΤΕΣ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ. Καθηγητής Καρδιολογίας

Effect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals

NT-proBNP A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure

Luisa Vinciguerra. Ictus recidivanti

Peri-operative Troponin Measurements - Pathophysiology and Prognosis

WHY ADMINISTER CARDIOTONIC AGENTS?

Rikshospitalet, University of Oslo

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Heart Failure Medical and Surgical Treatment

Treating HF Patients with ARNI s Why, When and How?

Introduction. Key words: cardiac biomarkers; short-term mortality; perioperative risk; non-cardiac surgery; coronary artery disease

ARIC Manuscript Proposal #2099. PC Reviewed: 3/12/13 Status: A Priority: 2 SC Reviewed: Status: Priority:

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

Introduction. Summary. Karim Gariani a, Alain Delabays b, Thomas V. Perneger c, Thomas Agoritsas a,c

*Christian M. Carlsen, 1 Mette Mouridsen, 1 Ahmad Sajadieh, 1 Lars Køber, 2 Olav W. Nielsen 1 ABSTRACT BACKGROUND

Supplementary Appendix

Acute Changes in Circulating Natriuretic Peptide Levels in Relation to Myocardial Ischemia

Pathophysiology and Diagnosis of Heart Failure

Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care

GDF-15 levels but not NTproBNP levels predict diastolic heart failure in morbid obesity

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Disclosures for Presenter

To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome

The Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?

CVD risk assessment using risk scores in primary and secondary prevention

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes


Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges

2017 ACC/AHA/HFSA HF guidelines. Advances in the Use of Biomarkers in Heart Failure Patients. Outline

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS

Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure

EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE

Heart failure (HF) is a disabling condition with high

Heart failure in diabetes: consequences for diagnosis and therapy

Heart Failure Treatment In Patients With Recurrent Myocardial Infarction

Joshua A. Beckman, MD. Brigham and Women s Hospital

N-Terminal Pro B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease

Supplementary Appendix

Edgar Hernández-Leiva 1*, Rodolfo Dennis 2, Daniel Isaza 3 and Juan Pablo Umaña 4

Diagnosis of heart failure in dogs with mitral valve disease

Citation for published version (APA): Lok, D. J. A. (2013). Novel markers in chronic heart failure. Groningen: s.n.

Βιοδείκτες στην καρδιακή ανεπάρκεια διαγνωστικά και θεραπευτικά δεδομένα. Χριστίνα Χρυσοχόου Επιμ Α Α Παν. Καρδιολογικής Κλινικής, ΙΓΝΑ

Clinical Outcome in Patients with Aortic Stenosis

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

Aortic stenosis aetiology: morphology of calcific AS,

Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.


UPDATES IN MANAGEMENT OF HF

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand

FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

Transcription:

BNP as a Predictor of Cardiovascular Disease and All Cause Mortality Dr. Thierry Le Jemtel

Outline Role of BNP and probnp as relevant biomarkers in cardiac conditions Role of BNP and probnp as relevant biomarkers in the general population Natriuretic Peptide and Metabolic Regulation

Brain Natriuretic Peptide Natriuretic peptides (NP) are hormones involved in the regulation of blood volume and blood pressure. ProBNP is secreted from the cardiac ventricles in response to increased myocardial wall stress due to volume overload and increased pressure. When probnp is released in the circulation it is cleaved in two equal parts: BNP and probnp

Differences between BNP and probnp: BNP is active probnp is not In whole blood BNP is stable for 24 hours and probnp for 72 hours. Amino acids: 32 for BNP and 76 for probnp. Half life is 20 min for BNP and 120 min for probnp. BNP is cleared by NPR C and neural endopeptidases, probnp by the kidney. BNP normal level is <100 pg/l, probnp normal level is <300 pg/l

Circulation 2004;109: 594 600

Int J Cardiol 2017; 228: 599 604

Hamada M et al Int J Cardiol 2017; 228: 599 604

Hamada M et al Int J Cardiol 2017; 228: 599 604

Forest plot of percent difference in log NTproBNP levels in African Americans, compared to Caucasians, overall and across subgroups of ARIC participants. Deepak K. Gupta et al. J Am Heart Assoc 2015;4:e001831

Cardiac Conditions

Base-Line Characteristics of 1586 Patients with Dyspnea Maisel, A. et al. N Engl J Med 2002;347:161 167

Box Plots Showing Median Levels of B-Type Natriuretic Peptide Measured in the Emergency Department in Three Groups of Patients Maisel, A. et al. N Engl J Med 2002;347:161 167

Multiple Logistic-Regression Analysis of Factors Used for Differentiating between Patients with and Those without Congestive Heart Failure Maisel, A. et al. N Engl J Med 2002;347:161 167

Relationship between NT-proBNP and BNP quartiles and the primary outcome evaluated by Coxregression models and incremental value of natriuretic peptides for the primary outcome according to body mass index categories. Wilson Nadruz, Jr et al. Circulation. 2016;134:1785-1787

From: Natriuretic Peptide Based Screening and Collaborative Care for Heart FailureThe STOP-HF Randomized Trial Figure Legend: Participant FlowBNP indicates brain-type natriuretic peptide. Ledwidge et al JAMA. 2013;310(1):66-74.

From: Natriuretic Peptide Based Screening and Collaborative Care for Heart FailureThe STOP-HF Randomized Trial Table Title: Baseline Participant Characteristics Ledwidge M et al JAMA. 2013;310(1):66-74.

Natriuretic Peptide Based Screening and Collaborative Care for Heart FailureThe STOP-HF Randomized Trial Figure Legend: Kaplan-Meier Analysis of Major Adverse Cardiovascular Events in the Full Study Sample and in Participants With BNP 50 pg/mlbnp indicates brain-type natriuretic peptide. Major adverse cardiovascular events included arrhythmia, transient ischemic attack, stroke, myocardial infarction, peripheral or pulmonary thrombosis/embolus, or heart failure. In the full sample, 51 (7.3%) of 697 patients were admitted for major adverse cardiovascular events in the intervention group and 71 (10.5%) of 677 were admitted in the control group. In participants with BNP 50 pg/ml, 35 (13.3%) of 263 were admitted for major adverse cardiovascular events in the intervention group and 45 (19.1%) of 235 were admitted in the control group. Ledwidge et al JAMA.2013;310(1):66-74

Lemos JA et al N Engl J Med 2001 345: 1014 1021

Lemos JA et al N Engl J Med 2001 345: 1014 1021

Caselli C et al Arterioscler Thromb Vasc Biol 2016;36:757 764

Caselli C et al Arterioscler Thromb Vasc Biol 2016;36:757 764

B type Natriuretic Peptide Predicts Morbidity and Long Term Mortality in Coronary Artery Bypass Grafting and Valve Surgery. Endicott KM 1, Amdur RL, Greenberg MD, Trachiotis GD Endicott KM et al Innovations 2016; 11:439 443

Clavel MA J Am Coll Cardiol 2016;68:1297 1307

Mentias A et al Am J Cardiol 2016; 117: 258 263

Pavasini R et al Chronic Respiratory Disease 2016 1 10

General population

Wang, T. et al. N Engl J Med 2004;350:655 663

Cumulative Incidence of Death (Panel A) and Heart Failure (Panel B), According to the Plasma B- Type Natriuretic Peptide Level at Base Line Wang, T. et al. N Engl J Med 2004;350:655 663

Multivariate Analysis of the Association of Plasma B-Type Natriuretic Peptide (BNP) Levels and Outcomes Wang, T. et al. N Engl J Med 2004;350:655-663 Wang, T. et al. N Engl J Med 2004;350:655 663

Huelsmann M et al J Am Coll Cardiol. 2013; 62: 1365 1372

Huelsmann M et al J Am Coll Cardiol. 2013; 62: 1365 1372

Huelsmann et al J Am Coll Cardiol. 2013; 62: 1365 1372

McKie PM Mayo Clin Proc 2011; 86:1154 1160

McKie P et al Mayo Clin Proc 2011; 86:1154 1160

Frequency distribution of plasma levels of N-terminal fragment of pro-b-type natriuretic peptide (NT-proBNP) and multivariable adjusted hazard ratios on the risk of cardiovascular events and all-cause mortality. Gerard C.M. Linssen et al. Eur Heart J 2010;31:120-127

Kaplan Meier plot for cardiovascular events by quintiles (Q) of N-terminal fragment of pro-btype natriuretic peptide (NT-proBNP). Gerard C.M. Linssen et al. Eur Heart J 2010;31:120-127

Dietl A et al PlOS ONE 2016 October 6

Dietl A et al PlOS ONE 2016 October 6

Dietl A et alplos ONE 2016 October 6

Abdullah SM et al Am J Cardiol 2005; 96:1284 1289

Cardiometabolic Regulation

Wang T N Engl J Med 2012; 367: 377 78

Zois NE et al Nat Rev Cardiol 2014; 11:403 412